ClinicalTrials.gg
CompletedNCT05186805Updated Sep 5, 2025Results posted

Maximal Use Study of Tapinarof Cream, 1% in Pediatric Subjects With Extensive Atopic Dermatitis

A Phase 2 interventional study of Tapinarof cream, 1% in Atopic Dermatitis, sponsored by Organon and Co. Completed at 10 sites in 2 countries. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2025-09-05.

Sponsored by Organon and Co · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
36
Allocation
Not applicable
Ages
2 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing tapinarof in Dermatitis, Atopic — 1 open to participants now, 2 under way, 1 of them phase 3. tapinarof · Dermatitis, Atopic.

Enrollment
8th of 12
36 · median 168
Started
2021
with 3 others
Phase 2
3 of 12
none open now
Registered
9th of 12
by date
Lead sponsor
5 of 12
Organon and Co

Among the 12 studies testing tapinarof in Dermatitis, Atopic, this one is the 8th largest by enrollment, is one of 4 that started in 2021, is one of 3 in phase 2, and was the 9th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

1 of the 12 studies testing tapinarof in Dermatitis, Atopic is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

About tapinarof

tapinarof: first FDA approval 2022 (VTAMA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 2 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing tapinarof in Dermatitis, Atopic, or all of them as a file.
02

Study summary

This is an open-label, multicenter study to evaluate the systemic exposure and safety of topical tapinarof cream, 1% under conditions of maximal use in pediatric subjects with atopic dermatitis

Read the detailed description

This is a 4-week open-label study in which subjects will be assigned to receive tapinarof cream, 1% once daily for 4 weeks. At the end of the 4-week study treatment, qualified subjects will have the option to enroll in an open-label, long-term extension study for an additional 48 weeks of treatment. Subjects who do not participate in the open-label, long-term extension study will complete a follow-up visit approximately one week after the end of treatment in this study.

03

Conditions studied

  • Atopic Dermatitis

Keywords

  • eczema
  • pediatric
  • tapinarof
  • phase 2
  • topical
04

Who can participate

Ages eligible
2 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female subjects age 2 to 17 with a confirmed clinical diagnosis of atopic dermatitis and present for at least 6 months for ages 6-17 years old, 3 months for ages 2-5 years old
  • BSA involvement ≥ 25% for subjects ages 12-17 years old, or ≥ 35% for subjects ages 2-11 years old, suitable for topical therapy.
  • vIGA-AD score of ≥ 3 at screening and baseline (pre-dose)
  • Female subjects of child bearing potential who are engaging in sexual activity that could lead to pregnancy agree to follow the specified guidance throughout the study
  • Capable of giving written
  • Negative pregnancy test at Baseline (Day 1)

Exclusion criteria

Exclusion Criteria:

  • at screening
  • Chronic or acute systemic or superficial infection requiring treatment with systemic antibacterials or antifungals within one week prior to baseline visit
  • Significant dermatological or inflammatory condition other than AD that, in the Investigator's opinion, would make it difficult to interpret data or assessments during the study
  • (ALT) or aspartate aminotransferase (AST) ≥2.0x the (ULN).
  • Screening total > 1.5x ULN
  • Current or chronic history of liver disease
  • Current or history of cancer within 5 years except for adequately treated cutaneous basal cell carcinoma, squamous cell carcinoma or carcinoma in situ of the cervix
  • Subjects who would not be considered suitable for topical therapy
  • Use of any prohibited medication or procedure within the indicated period before the baseline visit including other product within 30 days or 5 half-lives of the investigational product (whichever is longer)
  • History of or ongoing serious illness or medical, physical, or psychiatric condition(s) that, in the Investigator's opinion, may interfere with the subject's participation in the study, interpretation of results, or ability to understand and give .
  • Pregnant or lactating females
  • History of sensitivity to the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the -Investigator or Medical Monitor, contraindicates their participation
  • Previous known participation in a clinical study with tapinarof (previously known as GSK2894512 and WBI-1001)
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    tapinarof cream

    Tapinarof (DMVT-505) cream, 1% applied topically once daily

    Drug: Tapinarof cream, 1%

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants That Experienced Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Number of Participants that Experienced Adverse Events (AEs) and Serious Adverse Events (SAEs).

    Time frame: Baseline to Day 28 for subjects enrolling in Long-Term Extension (LTE), otherwise to Day 35

  2. Change From Baseline in Laboratory Values (U/L)

    Change in laboratory values was assessed for clinical relevance

    Time frame: Baseline to Day 28

  3. Change From Baseline in Laboratory Values (g/L)

    Change in laboratory values was assessed for clinical relevance

    Time frame: Baseline to Day 28

  4. Change From Baseline in Laboratory Values (mmol/L)

    Change in laboratory values was assessed for clinical relevance

    Time frame: Baseline to Day 28

  5. Change From Baseline in Laboratory Values (Umol/L)

    Change in laboratory values was assessed for clinical relevance

    Time frame: Baseline to Day 28

  6. Change From Baseline in Laboratory Values (10^9 Cells/L)

    Change in laboratory values was assessed for clinical relevance

    Time frame: Baseline to Day 28

  7. Change From Baseline in Laboratory Values (%)

    Change in laboratory values was assessed for clinical relevance

    Time frame: Baseline to Day 28

  8. Change From Baseline in Laboratory Values (pg)

    Change in Ery. mean corpuscular hemoglobin laboratory values was assessed for clinical relevance

    Time frame: Baseline to Day 28

  9. Change From Baseline in Laboratory Values (fL)

    Change in Ery. mean corpuscular volume laboratory values was assessed for clinical relevance

    Time frame: Baseline to Day 28

  10. Change From Baseline in Laboratory Values (10^12 Cells/L)

    Change in Erythrocytes laboratory values was assessed for clinical relevance

    Time frame: Baseline to Day 28

  11. Change From Baseline in Laboratory Values (L/L)

    Change in Hematocrit laboratory values was assessed for clinical relevance

    Time frame: Baseline to Day 28

  12. Mean Change in Local Tolerability Scale (LTS)

    Local Tolerability Scale (LTS) is a clinical tool for assessing the presence and overall degree of irritation at the application sites, according to a 5-point scale. 0 indicates no irritation and 4 indicates Very Severe irritation.

    Time frame: Baseline to Day 28

  13. Tapinarof Plasma PK Parameters on Day 1: AUC0-τ

    The AUC in plasma is a pharmacokinetic parameter that describes the overall exposure of the drug.

    Time frame: Day 1 (PK samples collected pre-dose and at 1, 3, and 5 hours post-dose)

  14. Tapinarof Plasma PK Parameters on Day 1: Cmax

    The Cmax is a pharmacokinetic parameter that describes the highest concentration of the drug that is achieved after dosing.

    Time frame: Day 1 (PK samples collected pre-dose and at 1, 3, and 5 hours post-dose)

  15. Tapinarof Plasma PK Parameters on Day 1: Tmax

    The tmax is a pharmacokinetic parameter that describes the time point at which the highest concentration of the drug is achieved after dosing.

    Time frame: Day 1 (PK samples collected pre-dose and at 1, 3, and 5 hours post-dose)

  16. Tapinarof Plasma Concentration: Cτ

    The Cτ is a pharmacokinetic parameter that is the last quantifiable concentration determined directly from individual concentration-time data

    Time frame: Day 1 (PK samples collected pre-dose and at 1, 3, and 5 hours post-dose)

  17. Change From Baseline in Vital Signs (Beats/Min)

    Change in pulse vital signs was assessed for clinical relevance

    Time frame: Baseline to Day 28

  18. Change From Baseline in Vital Signs (mmHg)

    Change in Blood Pressure vital signs was assessed for clinical relevance

    Time frame: Baseline to Day 28

  19. Change From Baseline in Vital Signs (C)

    Change in Temperature vital signs was assessed for clinical relevance

    Time frame: Baseline to Day 28

Secondary outcomes

  1. Change From Baseline in Validated Investigator Global Assessment in Atopic Dermatitis (vIGA-AD)

    The vIGA-AD is a global assessment of the current state of the disease. It is a static 5-point scale used to grade overall disease severity (scalp excluded), as determined by the investigator, using the clinical characteristics of erythema, induration/papulation, lichenification, oozing/crusting. The vIGA-AD ranges from 0 to 4 and is calculated as Clear (0), Almost clear (1), Mild (2), Moderate (3), and Severe (4). Higher vIGA-AD scores represent more severe disease.

    Time frame: Baseline to Day 28

  2. Number of Subjects Who Have a Validated Investigator Global Assessment in Atopic Dermatitis (vIGA-AD) Score of Almost Clear (0 or 1) and at Least a 2-grade Reduction From Baseline

    The vIGA-AD is a global assessment of the current state of the disease. It is a static 5-point scale used to grade overall disease severity (scalp excluded), as determined by the investigator, using the clinical characteristics of erythema, induration/papulation, lichenification, oozing/crusting. The vIGA-AD ranges from 0 to 4 and is calculated as Clear (0), Almost clear (1), Mild (2), Moderate (3), and Severe (4). Higher vIGA-AD scores represent more severe disease.

    Time frame: Baseline to Day 28

  3. Number of Subjects With ≥50%, Improvement in Eczema Area and Severity Index (EASI) Score

    The Eczema Area and Severity Index (EASI) is a scoring system that takes into account the overall severity of disease based on lesion severity and the extent of percent body surface area affected with atopic dermatitis. The EASI is a composite score ranging from 0 -72 that takes into account the degree of erythema, edema/papulation, excoriation, and lichenification (each scored from 0 to 3 separately) for each of four body regions, with adjustment for the percent body surface area involved for each body region relative to the whole body. A higher EASI score represents more severe disease.

    Time frame: Baseline to Day 28

  4. Number of Subjects With ≥75%, Improvement in Eczema Area and Severity Index (EASI) Score

    The EASI is a composite score ranging from 0 to 72 that takes into account the degree of erythema, edema/papulation, excoriation, and lichenification (each scored from 0 to 3 separately) for each of four body regions, with adjustment for the %BSA involved for each body region relative to the whole body. Higher EASI scores indicate more severe disease.

    Time frame: Baseline to Day 28

  5. Number of Subjects With ≥90%, Improvement in Eczema Area and Severity Index (EASI) Score

    The EASI is a composite score ranging from 0 to 72 that takes into account the degree of erythema, edema/papulation, excoriation, and lichenification (each scored from 0 to 3 separately) for each of four body regions, with adjustment for the %BSA involved for each body region relative to the whole body. Higher EASI scores indicate more severe disease.

    Time frame: Baseline to Day 28

  6. Mean Change in Eczema Area and Severity Index EASI From Baseline to Day 28

    The EASI is a composite score ranging from 0 to 72 that takes into account the degree of erythema, edema/papulation, excoriation, and lichenification (each scored from 0 to 3 separately) for each of four body regions, with adjustment for the %BSA involved for each body region relative to the whole body. Higher EASI scores indicate more severe disease.

    Time frame: Baseline to Day 28

  7. Percent Change in Eczema Area and Severity Index EASI From Baseline to Day 28

    The EASI is a composite score ranging from 0 to 72 that takes into account the degree of erythema, edema/papulation, excoriation, and lichenification (each scored from 0 to 3 separately) for each of four body regions, with adjustment for the %BSA involved for each body region relative to the whole body. Higher EASI scores indicate more severe disease.

    Time frame: Baseline to Day 28

  8. Mean Change in Percent of Total Body Surface Area (%BSA) Affected

    The assessment of %BSA affected is an estimate of the percentage of total involved skin with psoriasis. For the purpose of clinical estimation, the total palmar surface of the subject's palm and digits may be assumed to be approximately equivalent to 1% BSA. The %BSA affected by psoriasis will be evaluated (from 0% to 100%). %BSA is a static assessment made without reference to previous scores.

    Time frame: Baseline to Day 28

  9. Percent Change in Percent of Total Body Surface Area (%BSA) Affected

    The assessment of %BSA affected is an estimate of the percentage of total involved skin with psoriasis. For the purpose of clinical estimation, the total palmar surface of the subject's palm and digits may be assumed to be approximately equivalent to 1% BSA. The %BSA affected by psoriasis will be evaluated (from 0% to 100%). %BSA is a static assessment made without reference to previous scores.

    Time frame: Baseline to Day 28

  10. Mean Change in Total Body Surface Area (BSA) x Validated Investigator Global Assessment in Atopic Dermatitis (vIGA-AD) Values

    The vIGA-AD is a clinical tool for assessing the current state/severity of a subject's atopic dermatitis at a given timepoint. It is a static 5-point morphological assessment of overall disease severity using the clinical characteristics of erythema, induration/papulation, lichenification, oozing/crusting (0 indicates no inflammatory signs of atopic dermatitis and 4 indicates disease is widespread). The assessment of %BSA affected is an estimate of the percentage of total involved skin with psoriasis. For clinical estimation, the total palmar surface of the subject's palm and digits may be assumed to be approximately equivalent to 1% BSA. %BSA is a static assessment made without reference to previous scores and will be evaluated 0-100%. The computation is referenced below, and no unit is applicable for this outcome measure. A negative change indicates improvement in disease. \[Total Body Surface Area (BSA) x Validated Investigator Global Assessment in Atopic Dermatitis (vIGA-AD)\]

    Time frame: Baseline to Day 28

  11. Percent Change in Total Body Surface Area (BSA) x Validated Investigator Global Assessment in Atopic Dermatitis (vIGA-AD) Values

    The vIGA-AD is a clinical tool for assessing the current state/severity of a subject's atopic dermatitis at a given timepoint. It is a static 5-point morphological assessment of overall disease severity, as determined by the investigator, using the clinical characteristics of erythema, induration/papulation, lichenification, oozing/crusting. Score of 0 indicates no inflammatory signs of atopic dermatitis and a 4 indicates disease is widespread in extent. The assessment of %BSA affected is an estimate of the percentage of total involved skin with psoriasis. For the purpose of clinical estimation, the total palmar surface of the subject's palm and digits may be assumed to be approximately equivalent to 1% BSA. The %BSA affected by psoriasis will be evaluated (from 0% to 100%). %BSA is a static assessment made without reference to previous scores. Computation: Total Body Surface Area (BSA) x Validated Investigator Global Assessment in Atopic Dermatitis (vIGA-AD)

    Time frame: Baseline to Day 28

  12. Mean Change in Average Weekly Peak Pruritus Numerical Rating Scale (PP-NRS) Score

    The PP-NRS is a scale from 0-10 used to assess itch/pruritus severity over a 24-hour period which will be used daily to assess peak pruritus. Higher PP-NRS ratings represent more itch reported.

    Time frame: Baseline to Day 28

  13. Proportion of Subjects With a Baseline Peak Pruritus Numerical Rating Scale (PP-NRS) Score ≥4 Who Achieved ≥4-point Reduction in PP-NRS Score

    The PP-NRS is a scale from 0-10 used to assess itch/pruritus severity over a 24-hour period which will be used daily to assess peak pruritus. Higher PP-NRS ratings represent more itch reported.

    Time frame: Baseline to Day 28

07

Results

Posted Sep 5, 2025

Participant flow

Participants from the DMVT-505-2104 study had the option to participate in the open label extension study (DMVT-505-3103, NCT05142774).

Participant flow — Overall Study
MilestoneTapinarof Cream
Started36
Completed32
Not completed4

Outcome measures

PrimaryNumber of Participants That Experienced Adverse Events (AEs) and Serious Adverse Events (SAEs)

Number of Participants that Experienced Adverse Events (AEs) and Serious Adverse Events (SAEs).

Time frame:
Baseline to Day 28 for subjects enrolling in Long-Term Extension (LTE), otherwise to Day 35
Reported as:
Count of participants · Participants
Number of Participants That Experienced Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsTapinarof Cream
Experienced an AE8
Experienced an SAE0
PrimaryChange From Baseline in Laboratory Values (U/L)

Change in laboratory values was assessed for clinical relevance

Time frame:
Baseline to Day 28
Reported as:
Mean · U/L
Change From Baseline in Laboratory Values (U/L)
U/LTapinarof Cream
Alanine aminotransferase (U/L)1.9 ± 10.80
Alkaline phosphatase (U/L)0.7 ± 52.95
Aspartate aminotransferase (U/L)0.6 ± 6.44
PrimaryChange From Baseline in Laboratory Values (g/L)

Change in laboratory values was assessed for clinical relevance

Time frame:
Baseline to Day 28
Reported as:
Mean · g/L
Change From Baseline in Laboratory Values (g/L)
g/LTapinarof Cream
Albumin (g/L)-0.7 ± 2.72
Protein (g/L)-0.5 ± 4.20
Ery. mean corpuscular HGB Concentration (g/L)-1.7 ± 7.68
Hemoglobin (g/L)0.0 ± 7.61
PrimaryChange From Baseline in Laboratory Values (mmol/L)

Change in laboratory values was assessed for clinical relevance

Time frame:
Baseline to Day 28
Reported as:
Mean · mmol/L
Change From Baseline in Laboratory Values (mmol/L)
mmol/LTapinarof Cream
Bicarbonate (mmol/L)-0.3 ± 2.16
Calcium (mmol/L)-0.006 ± 0.0846
Chloride (mmol/L)0.0 ± 2.99
Glucose (mmol/L)0.20 ± 0.819
Potassium (mmol/L)0.08 ± 0.532
Sodium (mmol/L)0.1 ± 1.98
Blood urea nitrogen (mmol/L)-0.06 ± 0.989
PrimaryChange From Baseline in Laboratory Values (Umol/L)

Change in laboratory values was assessed for clinical relevance

Time frame:
Baseline to Day 28
Reported as:
Mean · Umol/L
Change From Baseline in Laboratory Values (Umol/L)
Umol/LTapinarof Cream
Bilirubin (umol/L)-0.34 ± 3.700
Enzymatic Creatinine (umol/L)-0.9 ± 7.66
Urate (umol/L)-6.0 ± 52.16
PrimaryChange From Baseline in Laboratory Values (10^9 Cells/L)

Change in laboratory values was assessed for clinical relevance

Time frame:
Baseline to Day 28
Reported as:
Mean · 10^9 cells/L
Change From Baseline in Laboratory Values (10^9 Cells/L)
10^9 cells/LTapinarof Cream
Basophils (10^9/L)0.01 ± 0.048
Eosinophils (10^9/L)0.00 ± 0.419
Leukocytes (10^9/L)0.71 ± 2.451
Lymphocytes (10^9/L)0.38 ± 1.095
Monocytes (10^9/L)-0.06 ± 0.175
Neutrophils (10^9/L)0.36 ± 2.124
Platelets (10^9/L)-34.8 ± 95.27
PrimaryChange From Baseline in Laboratory Values (%)

Change in laboratory values was assessed for clinical relevance

Time frame:
Baseline to Day 28
Reported as:
Mean · % of cells
Change From Baseline in Laboratory Values (%)
% of cellsTapinarof Cream
Basophils/Total cells (%)0.05 ± 0.343
Eosinophils/Total cells (%)-0.13 ± 4.606
Lymphocytes/Total cells (%)0.81 ± 11.023
Monocytes/Total cells (%)-0.81 ± 2.662
Neutrophils/Total cells (%)0.08 ± 12.693
Reticulocytes/Erythrocytes (%)0.06 ± 0.377
PrimaryChange From Baseline in Laboratory Values (pg)

Change in Ery. mean corpuscular hemoglobin laboratory values was assessed for clinical relevance

Time frame:
Baseline to Day 28
Reported as:
Mean · pg
Change From Baseline in Laboratory Values (pg)
pgTapinarof Cream
Change From Baseline in Laboratory Values (pg)0.26 ± 0.787
PrimaryChange From Baseline in Laboratory Values (fL)

Change in Ery. mean corpuscular volume laboratory values was assessed for clinical relevance

Time frame:
Baseline to Day 28
Reported as:
Mean · fL
Change From Baseline in Laboratory Values (fL)
fLTapinarof Cream
Change From Baseline in Laboratory Values (fL)1.26 ± 1.973
PrimaryChange From Baseline in Laboratory Values (10^12 Cells/L)

Change in Erythrocytes laboratory values was assessed for clinical relevance

Time frame:
Baseline to Day 28
Reported as:
Mean · 10^12 cells/L
Change From Baseline in Laboratory Values (10^12 Cells/L)
10^12 cells/LTapinarof Cream
Change From Baseline in Laboratory Values (10^12 Cells/L)-0.055 ± 0.2481
PrimaryChange From Baseline in Laboratory Values (L/L)

Change in Hematocrit laboratory values was assessed for clinical relevance

Time frame:
Baseline to Day 28
Reported as:
Mean · L/L
Change From Baseline in Laboratory Values (L/L)
L/LTapinarof Cream
Change From Baseline in Laboratory Values (L/L)0.002 ± 0.0228
PrimaryMean Change in Local Tolerability Scale (LTS)

Local Tolerability Scale (LTS) is a clinical tool for assessing the presence and overall degree of irritation at the application sites, according to a 5-point scale. 0 indicates no irritation and 4 indicates Very Severe irritation.

Time frame:
Baseline to Day 28
Reported as:
Mean · Units on a scale
Mean Change in Local Tolerability Scale (LTS)
Units on a scaleTapinarof Cream
Baseline0.2 ± 0.68
Day 280.1 ± 0.40
PrimaryTapinarof Plasma PK Parameters on Day 1: AUC0-τ

The AUC in plasma is a pharmacokinetic parameter that describes the overall exposure of the drug.

Time frame:
Day 1 (PK samples collected pre-dose and at 1, 3, and 5 hours post-dose)
Reported as:
Mean · pg*h/mL
Tapinarof Plasma PK Parameters on Day 1: AUC0-τ
pg*h/mLTapinarof Cream
Tapinarof Plasma PK Parameters on Day 1: AUC0-τ4690 ± 5600
PrimaryTapinarof Plasma PK Parameters on Day 1: Cmax

The Cmax is a pharmacokinetic parameter that describes the highest concentration of the drug that is achieved after dosing.

Time frame:
Day 1 (PK samples collected pre-dose and at 1, 3, and 5 hours post-dose)
Reported as:
Mean · pg/mL
Tapinarof Plasma PK Parameters on Day 1: Cmax
pg/mLTapinarof Cream
Tapinarof Plasma PK Parameters on Day 1: Cmax2440 ± 3900
PrimaryTapinarof Plasma PK Parameters on Day 1: Tmax

The tmax is a pharmacokinetic parameter that describes the time point at which the highest concentration of the drug is achieved after dosing.

Time frame:
Day 1 (PK samples collected pre-dose and at 1, 3, and 5 hours post-dose)
Reported as:
Mean · hour
Tapinarof Plasma PK Parameters on Day 1: Tmax
hourTapinarof Cream
Tapinarof Plasma PK Parameters on Day 1: Tmax2.37 ± 1.19
PrimaryTapinarof Plasma Concentration: Cτ

The Cτ is a pharmacokinetic parameter that is the last quantifiable concentration determined directly from individual concentration-time data

Time frame:
Day 1 (PK samples collected pre-dose and at 1, 3, and 5 hours post-dose)
Reported as:
Mean · pg/mL
Tapinarof Plasma Concentration: Cτ
pg/mLTapinarof Cream
Tapinarof Plasma Concentration: Cτ1330 ± 3780
PrimaryChange From Baseline in Vital Signs (Beats/Min)

Change in pulse vital signs was assessed for clinical relevance

Time frame:
Baseline to Day 28
Reported as:
Mean · Beats/Min
Change From Baseline in Vital Signs (Beats/Min)
Beats/MinTapinarof Cream
Change From Baseline in Vital Signs (Beats/Min)0.9 ± 14.40
PrimaryChange From Baseline in Vital Signs (mmHg)

Change in Blood Pressure vital signs was assessed for clinical relevance

Time frame:
Baseline to Day 28
Reported as:
Mean · mmHg
Change From Baseline in Vital Signs (mmHg)
mmHgTapinarof Cream
Systolic Blood Pressure (mmHg)1.1 ± 8.78
Diastolic Blood Pressure (mmHg)-0.9 ± 6.63
PrimaryChange From Baseline in Vital Signs (C)

Change in Temperature vital signs was assessed for clinical relevance

Time frame:
Baseline to Day 28
Reported as:
Mean · degrees C
Change From Baseline in Vital Signs (C)
degrees CTapinarof Cream
Change From Baseline in Vital Signs (C)-0.08 ± 0.402
SecondaryChange From Baseline in Validated Investigator Global Assessment in Atopic Dermatitis (vIGA-AD)

The vIGA-AD is a global assessment of the current state of the disease. It is a static 5-point scale used to grade overall disease severity (scalp excluded), as determined by the investigator, using the clinical characteristics of erythema, induration/papulation, lichenification, oozing/crusting. The vIGA-AD ranges from 0 to 4 and is calculated as Clear (0), Almost clear (1), Mild (2), Moderate (3), and Severe (4). Higher vIGA-AD scores represent more severe disease.

Time frame:
Baseline to Day 28
Reported as:
Count of participants · Participants
Change From Baseline in Validated Investigator Global Assessment in Atopic Dermatitis (vIGA-AD)
ParticipantsTapinarof Cream
+4 = worsened by 40
+3 = worsened by 30
+2 = worsened by 20
+1 = worsened by 10
0 - no change8
-1 = improved by 114
-2 = improved by 28
-3 = improved by 32
-4 = improved by 40
SecondaryNumber of Subjects Who Have a Validated Investigator Global Assessment in Atopic Dermatitis (vIGA-AD) Score of Almost Clear (0 or 1) and at Least a 2-grade Reduction From Baseline

The vIGA-AD is a global assessment of the current state of the disease. It is a static 5-point scale used to grade overall disease severity (scalp excluded), as determined by the investigator, using the clinical characteristics of erythema, induration/papulation, lichenification, oozing/crusting. The vIGA-AD ranges from 0 to 4 and is calculated as Clear (0), Almost clear (1), Mild (2), Moderate (3), and Severe (4). Higher vIGA-AD scores represent more severe disease.

Time frame:
Baseline to Day 28
Reported as:
Count of participants · Participants
Number of Subjects Who Have a Validated Investigator Global Assessment in Atopic Dermatitis (vIGA-AD) Score of Almost Clear (0 or 1) and at Least a 2-grade Reduction From Baseline
ParticipantsTapinarof Cream
Number of Subjects Who Have a Validated Investigator Global Assessment in Atopic Dermatitis (vIGA-AD) Score of Almost Clear (0 or 1) and at Least a 2-grade Reduction From Baseline8
SecondaryNumber of Subjects With ≥50%, Improvement in Eczema Area and Severity Index (EASI) Score

The Eczema Area and Severity Index (EASI) is a scoring system that takes into account the overall severity of disease based on lesion severity and the extent of percent body surface area affected with atopic dermatitis. The EASI is a composite score ranging from 0 -72 that takes into account the degree of erythema, edema/papulation, excoriation, and lichenification (each scored from 0 to 3 separately) for each of four body regions, with adjustment for the percent body surface area involved for each body region relative to the whole body. A higher EASI score represents more severe disease.

Time frame:
Baseline to Day 28
Reported as:
Count of participants · Participants
Number of Subjects With ≥50%, Improvement in Eczema Area and Severity Index (EASI) Score
ParticipantsTapinarof Cream
Number of Subjects With ≥50%, Improvement in Eczema Area and Severity Index (EASI) Score20
SecondaryNumber of Subjects With ≥75%, Improvement in Eczema Area and Severity Index (EASI) Score

The EASI is a composite score ranging from 0 to 72 that takes into account the degree of erythema, edema/papulation, excoriation, and lichenification (each scored from 0 to 3 separately) for each of four body regions, with adjustment for the %BSA involved for each body region relative to the whole body. Higher EASI scores indicate more severe disease.

Time frame:
Baseline to Day 28
Reported as:
Count of participants · Participants
Number of Subjects With ≥75%, Improvement in Eczema Area and Severity Index (EASI) Score
ParticipantsTapinarof Cream
Number of Subjects With ≥75%, Improvement in Eczema Area and Severity Index (EASI) Score7
SecondaryNumber of Subjects With ≥90%, Improvement in Eczema Area and Severity Index (EASI) Score

The EASI is a composite score ranging from 0 to 72 that takes into account the degree of erythema, edema/papulation, excoriation, and lichenification (each scored from 0 to 3 separately) for each of four body regions, with adjustment for the %BSA involved for each body region relative to the whole body. Higher EASI scores indicate more severe disease.

Time frame:
Baseline to Day 28
Reported as:
Count of participants · Participants
Number of Subjects With ≥90%, Improvement in Eczema Area and Severity Index (EASI) Score
ParticipantsTapinarof Cream
Number of Subjects With ≥90%, Improvement in Eczema Area and Severity Index (EASI) Score4
SecondaryMean Change in Eczema Area and Severity Index EASI From Baseline to Day 28

The EASI is a composite score ranging from 0 to 72 that takes into account the degree of erythema, edema/papulation, excoriation, and lichenification (each scored from 0 to 3 separately) for each of four body regions, with adjustment for the %BSA involved for each body region relative to the whole body. Higher EASI scores indicate more severe disease.

Time frame:
Baseline to Day 28
Reported as:
Mean · scores on a scale
Mean Change in Eczema Area and Severity Index EASI From Baseline to Day 28
scores on a scaleTapinarof Cream
Mean Change in Eczema Area and Severity Index EASI From Baseline to Day 28-12.16 ± 9.742
SecondaryPercent Change in Eczema Area and Severity Index EASI From Baseline to Day 28

The EASI is a composite score ranging from 0 to 72 that takes into account the degree of erythema, edema/papulation, excoriation, and lichenification (each scored from 0 to 3 separately) for each of four body regions, with adjustment for the %BSA involved for each body region relative to the whole body. Higher EASI scores indicate more severe disease.

Time frame:
Baseline to Day 28
Reported as:
Mean · % change from baseline
Percent Change in Eczema Area and Severity Index EASI From Baseline to Day 28
% change from baselineTapinarof Cream
Percent Change in Eczema Area and Severity Index EASI From Baseline to Day 28-53.38 ± 38.337
SecondaryMean Change in Percent of Total Body Surface Area (%BSA) Affected

The assessment of %BSA affected is an estimate of the percentage of total involved skin with psoriasis. For the purpose of clinical estimation, the total palmar surface of the subject's palm and digits may be assumed to be approximately equivalent to 1% BSA. The %BSA affected by psoriasis will be evaluated (from 0% to 100%). %BSA is a static assessment made without reference to previous scores.

Time frame:
Baseline to Day 28
Reported as:
Mean · percentage of BSA
Mean Change in Percent of Total Body Surface Area (%BSA) Affected
percentage of BSATapinarof Cream
Mean Change in Percent of Total Body Surface Area (%BSA) Affected-21.06 ± 18.789
SecondaryPercent Change in Percent of Total Body Surface Area (%BSA) Affected

The assessment of %BSA affected is an estimate of the percentage of total involved skin with psoriasis. For the purpose of clinical estimation, the total palmar surface of the subject's palm and digits may be assumed to be approximately equivalent to 1% BSA. The %BSA affected by psoriasis will be evaluated (from 0% to 100%). %BSA is a static assessment made without reference to previous scores.

Time frame:
Baseline to Day 28
Reported as:
Mean · % change from baseline
Percent Change in Percent of Total Body Surface Area (%BSA) Affected
% change from baselineTapinarof Cream
Percent Change in Percent of Total Body Surface Area (%BSA) Affected-49.40 ± 41.3000
SecondaryMean Change in Total Body Surface Area (BSA) x Validated Investigator Global Assessment in Atopic Dermatitis (vIGA-AD) Values

The vIGA-AD is a clinical tool for assessing the current state/severity of a subject's atopic dermatitis at a given timepoint. It is a static 5-point morphological assessment of overall disease severity using the clinical characteristics of erythema, induration/papulation, lichenification, oozing/crusting (0 indicates no inflammatory signs of atopic dermatitis and 4 indicates disease is widespread). The assessment of %BSA affected is an estimate of the percentage of total involved skin with psoriasis. For clinical estimation, the total palmar surface of the subject's palm and digits may be assumed to be approximately equivalent to 1% BSA. %BSA is a static assessment made without reference to previous scores and will be evaluated 0-100%. The computation is referenced below, and no unit is applicable for this outcome measure. A negative change indicates improvement in disease. \[Total Body Surface Area (BSA) x Validated Investigator Global Assessment in Atopic Dermatitis (vIGA-AD)\]

Time frame:
Baseline to Day 28
Reported as:
Mean · unitless
Mean Change in Total Body Surface Area (BSA) x Validated Investigator Global Assessment in Atopic Dermatitis (vIGA-AD) Values
unitlessTapinarof Cream
Mean Change in Total Body Surface Area (BSA) x Validated Investigator Global Assessment in Atopic Dermatitis (vIGA-AD) Values-85.15 ± 65.848
SecondaryPercent Change in Total Body Surface Area (BSA) x Validated Investigator Global Assessment in Atopic Dermatitis (vIGA-AD) Values

The vIGA-AD is a clinical tool for assessing the current state/severity of a subject's atopic dermatitis at a given timepoint. It is a static 5-point morphological assessment of overall disease severity, as determined by the investigator, using the clinical characteristics of erythema, induration/papulation, lichenification, oozing/crusting. Score of 0 indicates no inflammatory signs of atopic dermatitis and a 4 indicates disease is widespread in extent. The assessment of %BSA affected is an estimate of the percentage of total involved skin with psoriasis. For the purpose of clinical estimation, the total palmar surface of the subject's palm and digits may be assumed to be approximately equivalent to 1% BSA. The %BSA affected by psoriasis will be evaluated (from 0% to 100%). %BSA is a static assessment made without reference to previous scores. Computation: Total Body Surface Area (BSA) x Validated Investigator Global Assessment in Atopic Dermatitis (vIGA-AD)

Time frame:
Baseline to Day 28
Reported as:
Mean · % change from baseline
Percent Change in Total Body Surface Area (BSA) x Validated Investigator Global Assessment in Atopic Dermatitis (vIGA-AD) Values
% change from baselineTapinarof Cream
Percent Change in Total Body Surface Area (BSA) x Validated Investigator Global Assessment in Atopic Dermatitis (vIGA-AD) Values-62.77 ± 35.290
SecondaryMean Change in Average Weekly Peak Pruritus Numerical Rating Scale (PP-NRS) Score

The PP-NRS is a scale from 0-10 used to assess itch/pruritus severity over a 24-hour period which will be used daily to assess peak pruritus. Higher PP-NRS ratings represent more itch reported.

Time frame:
Baseline to Day 28
Reported as:
Mean · Units on a scale
Mean Change in Average Weekly Peak Pruritus Numerical Rating Scale (PP-NRS) Score
Units on a scaleTapinarof Cream
Mean Change in Average Weekly Peak Pruritus Numerical Rating Scale (PP-NRS) Score-4.155 ± 2.4558
SecondaryProportion of Subjects With a Baseline Peak Pruritus Numerical Rating Scale (PP-NRS) Score ≥4 Who Achieved ≥4-point Reduction in PP-NRS Score

The PP-NRS is a scale from 0-10 used to assess itch/pruritus severity over a 24-hour period which will be used daily to assess peak pruritus. Higher PP-NRS ratings represent more itch reported.

Time frame:
Baseline to Day 28
Reported as:
Count of participants · Participants
Proportion of Subjects With a Baseline Peak Pruritus Numerical Rating Scale (PP-NRS) Score ≥4 Who Achieved ≥4-point Reduction in PP-NRS Score
ParticipantsTapinarof Cream
Achieved ≥ 4-Point Reduction from Baseline in the Average Weekly PP-NRS Score14
Failure to Achieve a ≥ 4-point Reduction from Baseline in the Average Weekly PP-NRS Score18

Adverse events

Collected over Baseline to Day 28 for subjects enrolling in Long-Term Extension (LTE), otherwise to Day 35. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tapinarof Cream0/36 (0%)0/36 (0%)8/36 (22.2%)
Most frequent other events
Most frequent other events
EventTapinarof Cream
HeadacheNervous system disorders3/36
VomitingGastrointestinal disorders2/36
NauseaGastrointestinal disorders1/36
FolliculitisInfections and infestations1/36
InfluenzaInfections and infestations1/36
PustuleInfections and infestations1/36
LymphadenopathyBlood and lymphatic system disorders1/36
Tranaminases increasedInvestigations1/36
ErythemaSkin and subcutaneous tissue disorders1/36

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Tapinarof Cream
<=18 years36
Between 18 and 65 years0
>=65 years0
Age, Continuous
Age, Continuous(years)Tapinarof Cream
Mean8.9 ± 4.85
Sex: Female, Male
Sex: Female, Male(Participants)Tapinarof Cream
Female12
Male24
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Tapinarof Cream
Hispanic or Latino18
Not Hispanic or Latino18
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Tapinarof Cream
American Indian or Alaska Native0
Asian3
Native Hawaiian or Other Pacific Islander0
Black or African American6
White27
More than one race0
Unknown or Not Reported0
Validated Investigator Global Assessment for Atopic Dermatitis
Validated Investigator Global Assessment for Atopic Dermatitis(Participants)Tapinarof Cream
0 - Clear0
1 - Almost Clear0
2 - Mild0
3 - Moderate28
4 - Severe8
08

Study locations

10 sites
  • Dermavant Investigative Site
    Thousand Oaks, California 91320, United States
  • Dermavant Investigative Site
    Centennial, Colorado 80112, United States
  • Dermavant Investigative Site
    Coral Gables, Florida 33146, United States
  • Dermavant Investigative Site
    Hialeah, Florida 33016, United States
  • Dermavant Investigative Site
    Miami Lakes, Florida 33014, United States
  • Dermavant Investigative Site
    Chicago, Illinois 60611, United States
  • Dermavant Investigative Site
    Summerville, South Carolina 29445, United States
  • Dermavant Investigative Site
    Houston, Texas 77030, United States
  • Dermavant Investigative Site
    San Antonio, Texas 78213, United States
  • Dermavant Investigative Site
    Calgary, Alberta T3A 2N1, Canada
09

References and documents

Publications

  • Bashaw ED, Tran DC, Shukla CG, Liu X. Maximal Usage Trial: An Overview of the Design of Systemic Bioavailability Trial for Topical Dermatological Products. Ther Innov Regul Sci. 2015 Jan;49(1):108-115. doi: 10.1177/2168479014539157. Epub 2014 Jun 27. PubMed 26634191 ↗
  • Bieber T. Atopic dermatitis. N Engl J Med. 2008 Apr 3;358(14):1483-94. doi: 10.1056/NEJMra074081. No abstract available. PubMed 18385500 ↗
  • Cappon GD and Hurtt ME. Developmental toxicity of the kidney. In: Kapp RW and Yyl L, editors. Reproductive Toxicology, Target Organ Series, 3rd edition. New York:Informa Healthcare, 2010:193-204.
  • Carroll CL, Balkrishnan R, Feldman SR, Fleischer AB Jr, Manuel JC. The burden of atopic dermatitis: impact on the patient, family, and society. Pediatr Dermatol. 2005 May-Jun;22(3):192-9. doi: 10.1111/j.1525-1470.2005.22303.x. PubMed 15916563 ↗
  • Frazier KS and Seely JC. Urinary system. In: Sahota PS, Popp JA, Hardisty JF and Gopinath C, editors. Toxicologic Pathology. Nonclinical Safety Assessment. CRC Press, 2013:421-84.
  • Furue M, Hashimoto-Hachiya A, Tsuji G. Aryl Hydrocarbon Receptor in Atopic Dermatitis and Psoriasis. Int J Mol Sci. 2019 Oct 31;20(21):5424. doi: 10.3390/ijms20215424. PubMed 31683543 ↗
  • Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Dermato-Venereologica Supplementum. 1980;92:44-7.
  • Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol. 2001 Feb;10(1):11-8. doi: 10.1034/j.1600-0625.2001.100102.x. PubMed 11168575 ↗
  • Kalia YN, Nonato LB, Lund CH, Guy RH. Development of skin barrier function in premature infants. J Invest Dermatol. 1998 Aug;111(2):320-6. doi: 10.1046/j.1523-1747.1998.00289.x. PubMed 9699737 ↗
  • Lewis-Jones S. Quality of life and childhood atopic dermatitis: the misery of living with childhood eczema. Int J Clin Pract. 2006 Aug;60(8):984-92. doi: 10.1111/j.1742-1241.2006.01047.x. PubMed 16893440 ↗
  • Nikolovski J, Stamatas GN, Kollias N, Wiegand BC. Barrier function and water-holding and transport properties of infant stratum corneum are different from adult and continue to develop through the first year of life. J Invest Dermatol. 2008 Jul;128(7):1728-36. doi: 10.1038/sj.jid.5701239. Epub 2008 Jan 17. PubMed 18200056 ↗
  • Peppers J, Paller AS, Maeda-Chubachi T, Wu S, Robbins K, Gallagher K, Kraus JE. A phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of atopic dermatitis. J Am Acad Dermatol. 2019 Jan;80(1):89-98.e3. doi: 10.1016/j.jaad.2018.06.047. Epub 2018 Jul 3. PubMed 30554600 ↗
  • Smith SH, Jayawickreme C, Rickard DJ, Nicodeme E, Bui T, Simmons C, Coquery CM, Neil J, Pryor WM, Mayhew D, Rajpal DK, Creech K, Furst S, Lee J, Wu D, Rastinejad F, Willson TM, Viviani F, Morris DC, Moore JT, Cote-Sierra J. Tapinarof Is a Natural AhR Agonist that Resolves Skin Inflammation in Mice and Humans. J Invest Dermatol. 2017 Oct;137(10):2110-2119. doi: 10.1016/j.jid.2017.05.004. Epub 2017 Jun 6. PubMed 28595996 ↗
  • Zoetis T, Hurtt ME. Species comparison of anatomical and functional renal development. Birth Defects Res B Dev Reprod Toxicol. 2003 Apr;68(2):111-20. doi: 10.1002/bdrb.10013. No abstract available. PubMed 12866702 ↗
  • Paller AS, Hebert AA, Gonzalez ME, Butners V, Fitzgerald N, Tabolt G, Rubenstein DS, Piscitelli SC. Maximal Usage Trial of Tapinarof Cream 1% Once Daily in Pediatric Patients Down to 2 Years of Age with Extensive Atopic Dermatitis. Am J Clin Dermatol. 2025 May;26(3):449-456. doi: 10.1007/s40257-025-00929-9. Epub 2025 Mar 24. PubMed 40126804 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2021 to primary completion in Aug 2022, 9 months.

Results were first posted in Sep 2025, 3 years after primary completion. A results delay was requested in Jan 2023.

Of 196 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's 9 months is below that.

Counting every sponsor, half of 224 studies reached it within 14 months; a quarter within 10 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2021
First posted
Jan 11, 2022
StartActual
Nov 15, 2021
Primary completionActual
Aug 24, 2022
CompletionActual
Aug 24, 2022
Results delay requested
Jan 11, 2023
Results first posted
Sep 5, 2025
Last update
Sep 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05186805
Lead sponsor
Organon and Co
Responsible party
Sponsor
First posted
Jan 11, 2022
Start date
Nov 15, 2021
Primary completion
Aug 24, 2022
Completion
Aug 24, 2022
Results posted
Sep 5, 2025
Last update
Sep 5, 2025

Study contacts

Diana Villalobos
study director · Dermavant Sciences, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tapinarof

Start the discussion